Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12923819 | 0.92 | PTGDR (0.85) | PTGDRTBXA2R | |
| SCHEMBL18269299 | 0.92 | PTGDR (0.85) | PTGDRTBXA2R | |
| SCHEMBL14514981 | 0.92 | PTGDR (0.84) | PTGDRTBXA2R | |
| SCHEMBL6935578 | 0.90 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL633588 | 0.90 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL6150895 | 0.90 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL1224329 | 0.90 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL6936201 | 0.90 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL6936207 | 0.90 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL5176774 | 0.85 | PTGDR (0.74) | PTGDRTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222235-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | SHIONOGI & CO., LTD. (JP) | 2005-10-06 | — | — | US | claimed |
| EP-1535629-A1 | DRUGS FOR IMPROVING THE PROGNOSIS OF BRAIN INJURY AND A METHOD OF SCREENING THE SAME | Japan Science and Technology Agency (JP) | 2005-06-01 | — | — | EP | claimed |
| US-8568967-B2 | Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-1882937-B1 | METHOD FOR DIAGNOSIS OF SEVERITY AND PREDICTION OF RECURRENCE IN EOSINOPHILIC INFLAMMATORY DISEASE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20100138937-A1 | Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease | AROS ELECTRONICS AB (SE) | 2010-06-03 | — | — | US | disclosed |
| EP-1882937-A1 | METHOD FOR DIAGNOSIS OF SEVERITY AND PREDICTION OF RECURRENCE IN EOSINOPHILIC INFLAMMATORY DISEASE | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-30 | — | — | EP | disclosed |
| EP-1598065-A2 | Drugs for improving prognosis of brain injury | Japan Science and Technology Agency (JP) | 2005-11-23 | — | — | EP | disclosed |
| US-20050227984-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| US-20050222235-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | SHIONOGI & CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1535629-A1 | DRUGS FOR IMPROVING THE PROGNOSIS OF BRAIN INJURY AND A METHOD OF SCREENING THE SAME | Japan Science and Technology Agency (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222235-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | HPGDS, PTGDR, PTGDR2 | PTGDR 2/4885TBXA2R 34/4885 |
| US-20050227984-A1 | Drugs for improving the prognosis of brain injury and a method of screening the same | HPGDS, PTGDR, PTGDR2 | PTGDR 2/4885TBXA2R 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.